C2917373||HIV-1 integrase inhibitor
C0013203||resistance
C0087111||treatment
C1705493||West
C0036453||Scotland
C0376601||integrase inhibitor
C0013203||resistance
C0684224||reported
C2603343||study
C0376601||integrase inhibitor
C0013203||resistance
C0036453||Scotland
C0877124||genotypic integrase resistance testing
C2348561||study population
C0087111||treatment
C0019699||HIV positive
C1550655||patient samples
C1963724||anti-retroviral therapy
C0017256||amplified
C1294197||sequenced
C0442726||detected
C0376601||integrase inhibitor
C0013203||resistance
C1550655||patient sample
C0026882||non-polymorphic mutation
C2606637||elvitegravir
C0013203||resistance
C2606637||elvitegravir
C0205103||intermediate
C0013203||resistance
C1871526||raltegravir
C0026882||accessory mutations
C0012655||susceptibility
C0376601||integrase inhibitors
C0376601||integrase inhibitor
C0013203||resistance
C2603343||study
C0376601||integrase
C0013203||resistance